Alnylam Pharmaceuticals Inc. has seen a notable increase in its stock price, reflecting positive investor sentiment and upcoming financial updates.
Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is rising today, gaining 3.59% to close at CA$232.53. This uptick comes as the company prepares to release its third-quarter financial results later this month, generating optimism among investors.
Investor takeaway: The upcoming financial results and the company's strong position in the RNAi therapeutics market are driving interest and investment in Alnylam, despite some recent volatility.
Advertisement
Alnylam Pharmaceuticals Inc
ALNY.US
ALNY.US
Alnylam Pharmaceuticals Inc
WealthAwesomeMarket cap
$29.95B
P/E
37.7x
52W high
$495.55
52W low
$197.81
1W change
+0.03%
Beta
0.27
Analyst Price Targets
Based on 29 analysts covering ALNY · as of Oct 12, 2026
Wall Street analysts forecast ALNY stock price to rise 65.1% over the next 12 months.
Consensus
Buy4.31 / 5.00
Avg. Target
C$370.55
+65.1% Upside
Previously C$371.12 on Oct 5, 2026
Current Price
C$224.47
Last close
Analyst Breakdown (29 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ALNY's historical volatility
30-Day Vol
46.9%
Annualized
90-Day Vol
70.6%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$187.76
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$211.50 | C$179.90 – C$248.64 |
| 60 trading days | C$199.28 | C$158.52 – C$250.51 |
| 90 trading days | C$187.76 | C$141.87 – C$248.49 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Market Cap Reaches CA$30 Billion
Alnylam's market capitalization has now reached CA$30.04 billion, reflecting its significant presence in the biopharmaceutical sector and investor confidence in its growth potential.
Bull case
Alnylam's strong pipeline and innovative RNA interference technology set it up well for future growth. Investors expect continued revenue increases and successful product launches, which could further boost the company's standing in the market.
Bear case
However, there are concerns about slower demand growth for its flagship product, AMVUTTRA. A recent cut in sales guidance has also created uncertainty, which could affect investor confidence moving forward.
Upcoming Financial Results
Advertisement
Alnylam is set to report its third-quarter financial results on October 29, 2026. This announcement is highly anticipated as it will provide insights into the company's performance and future expectations, particularly regarding its TTR drug franchise.
Market Position and Pipeline
As a leader in RNAi therapeutics, Alnylam has a strong pipeline with multiple products in development. The company has seen substantial revenue growth, focusing on expanding its offerings and improving treatment outcomes for patients worldwide.
Investor Sentiment
Despite recent challenges, investor sentiment remains positive due to Alnylam's innovative approach and potential for future growth. The stock's rise today reflects a renewed confidence in the company's ability to navigate the competitive biopharmaceutical landscape.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
